Skip to content

A correlative study to predict the pathological response to neoadjuvant therapy for esophageal cancer

A correlative study to predict the pathological response to neoadjuvant therapy for esophageal cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500110492
Enrollment
Unknown
Registered
2025-10-14
Start date
2025-10-24
Completion date
Unknown
Last updated
2025-10-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal cancer

Interventions

Observation group:None

Sponsors

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: pathological diagnosis of esophageal adenocarcinoma (EAC),esophageal squamous cell carcinoma (ESCC), or esophageal adenosquamous carcinoma; underwent MIE; at least 3 months of postoperative follow-up with complete follow-up data available; and at least 18 years of age and capable of understanding the study objectives to comply with the follow up procedures.

Exclusion criteria

Exclusion criteria: the presence of distant metastasis (defined as M1 stage according to the 8th edition of the AJCC TNM classification) or concomitant malignant tumors before esophagectomy; a history of chronic pain (defined as pain persisting for more than 3 months, including chronic low back pain, arthritis-related pain, or neuropathic pain) or a preoperative diagnosis of a mental disorder (including major depressive disorder, generalized anxiety disorder, bipolar disorder, or schizophrenia); the presence of severe infection, hematologic disease, or autoimmune disease; and incomplete clinical data or a follow-up duration of less than 3 months.

Design outcomes

Primary

MeasureTime frame
Laboratory results;Inflammation indicators;

Secondary

MeasureTime frame
General information;Acute and chronic pain, depression and tumor prognosis;Ancillary test results;pathological staging;

Countries

China

Contacts

Public ContactYan Tao

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

blizzardyt@163.com+86 135 2255 3375

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026